Article
Medicine, General & Internal
David Robert Grimes, Edward M. A. Corry, Talia Malagon, Ciaran O'Riain, Eduardo L. Franco, Donal J. Brennan
Summary: The study compared different cervical cancer screening modalities on a simulated population of women aged >= 25 years, considering the increasing uptake of the HPV vaccine. HPV-based modalities outperformed LBC-based approaches, with reflex approaches and appropriate test intervals maximizing therapeutic efficacy. Increasing HPV vaccination rates resulted in fewer unnecessary colposcopies with HPV-based screening approaches.
Article
Immunology
Gabriella Di Giuseppe, Lucio Folcarelli, Raffaele Lanzano, Francesco Napolitano, Maria Pavia
Summary: This study assessed the awareness, attitudes, and uptake of HPV vaccination and cervical cancer screening in detained women. The findings showed a low level of awareness of HPV infection and a lack of adherence to prevention measures. Evidence-based interventions are needed to promote participation in HPV vaccination and cervical cancer screening programs among incarcerated women.
Article
Oncology
Shreya Desai, Michelle J. Zhu, Ilana Lapidos-Salaiz
Summary: Low- and middle-income countries bear a high burden of preventable cervical cancer cases and deaths, with human papillomavirus DNA-based testing increasingly being the preferred screening method. This commentary discusses next steps and key considerations for the expansion of this screening approach.
Editorial Material
Virology
Guorong Li, Maryame Lamsisi, Sara Chenafi, Louise Moniod, Abdelhamid Benlghazi, Moulay Mustapha Ennaji, Celine Chauleur, Thomas Bourlet
Summary: Cervical cancer can be prevented by detecting the human papillomavirus (HPV). The World Health Organization called for the elimination of cervical cancer by 2030 and regular screening programs are crucial. However, low screening rates in both developing and developed countries hinder progress due to women's reluctance to participate in gynecologic examinations. Urine-based HPV detection is a convenient and affordable solution to improve screening coverage, but standardized tests are currently lacking. Optimizing protocols and standardizing urinary HPV detection will facilitate its clinical implementation, contributing significantly to WHO's goal of global elimination of cervical cancer.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Mariko Taniguchi, Yutaka Ueda, Asami Yagi, Ai Miyoshi, Yusuke Tanaka, Ryoko Minekawa, Masayuki Endo, Takuji Tomimatsu, Kei Hirai, Tomio Nakayama, Tadashi Kimura
Summary: Women born between 1994 and 1999 with high HPV vaccination rates in Japan are now at the age for cervical cancer screening. Research showed that vaccinated women had better health awareness, while unvaccinated women were more influenced by fear of cancer. Tailored leaflets recommending screening increased rates slightly for both groups, indicating potential for improving cervical cancer control measures tailored to HPV vaccination status.
Review
Health Care Sciences & Services
Sok King Ong, Sarah K. Abe, Shyamala Thilagaratnam, Rei Haruyama, Ruchi Pathak, Harindra Jayasekara, Kayo Togawa, Aliza K. C. Bhandari, Abhishek Shankar, Ashrafun Nessa, Uranbolor Jugder, Julyanti Agustina, Mohammed Biglari, Aasim Yusuf, Ugyen Tshomo, Eshani Fernando, Clarito Cairo, Kyaw Kan Kaung, Beauta Rath, Champadeng Vongdala, Kishore Kumar Pradhananga, Jeongseon Kim, Youn Kyung Chung, Tran Thi Thanh Huong, Suleeporn Sangrajran, Yawei Zhang, Partha Basu, Yin Ling Woo, Babu Sukumaran, William Y. K. Hwang
Summary: About 95% of global cervical cancers are caused by HPV. Cervical cancer can be prevented and cured through early detection and treatment. This study reviewed national cervical cancer indicators and barriers to HPV vaccination and cervical cancer screening in 21 Asian countries. It found that half of the countries have introduced HPV vaccination, but only five countries reported screening uptake of over 50%.
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2023)
Review
Medicine, General & Internal
Flavia M. Correa, Arn Migowski, Liz M. De Almeida, Marcelo A. Soares
Summary: This review discusses the current strategies in Brazil for screening, treatment, and prevention (HPV vaccination) against cervical cancer, highlighting the country's large public health system and the disparities in access to healthcare. It also explores the potential integration of newer technologies to eliminate cervical cancer.
FRONTIERS IN MEDICINE
(2022)
Article
Obstetrics & Gynecology
Sylvia Kaljouw, Erik E. L. Jansen, Clare A. Aitken, Inge M. C. M. de Kok
Summary: The harms and benefits of cervical cancer screening in the first three rounds of the Dutch hrHPV screening program were evaluated. The number of screening tests and CIN2(+) diagnoses decreased over the rounds, while the efficiency of screening varied based on age groups. Longer screening intervals were found to be more efficient for older women. This study highlights the importance of considering age-specific factors in cervical cancer screening programs.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2022)
Article
Immunology
Khulud Ahmad Rezq, Maadiah Algamdi, Raghad Alanazi, Sarah Alanazi, Fatmah Alhujairy, Radwa Albalawi, Wafa Al-Zamaa
Summary: This cross-sectional study aimed to assess Saudi women's knowledge, perceptions, and acceptance of HPV vaccination and cervical cancer screening. Data were collected through online questionnaires from April 1, 2023, to May 30, 2023. The study found that 70% of the participants had fair knowledge, while 30% had good knowledge on the topic. Acceptance was more correlated with perception than with knowledge, but the correlation remained weak. Fear of side effects and skepticism about effectiveness were identified as the main barriers to vaccine uptake.
Article
Oncology
Cecilia Acuti Martellucci, Margherita Morettini, Julia M. L. Brotherton, Karen Canfell, Lamberto Manzoli, Maria Elena Flacco, Matthew Palmer, Paolo Giorgi Rossi, Mose Martellucci, Giusi Giacomini, Marcello Mario D'Errico, Francesca Pasqualini
Summary: In a study conducted in central Italy, catch-up HPV vaccination was found to significantly reduce the risk of cervical abnormalities detected in organized screening and provide herd protection to unvaccinated women.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Public, Environmental & Occupational Health
Debi L. Smith, Rebecca B. Perkins
Summary: This commentary discusses the differences in rates of on-time HPV vaccination and cervical cancer screening among enrollees in different insurance plans in 2018, as described by Richards et al. The authors also highlight the broader problem of low HPV vaccination rates and decreasing cervical cancer screening rates across all sectors. They outline the challenges posed by the COVID-19 pandemic on these prevention measures and discuss opportunities for improvement.
PREVENTIVE MEDICINE
(2022)
Article
Multidisciplinary Sciences
Uraiwan Khomphaiboonkij, Nattapong Sreamsukcharoenchai, Supakorn Pitakkarnkul, Kristsanamon Rittiluechai, Siriwan Tangjitgamol
Summary: Knowledge about cervical cancer screening and HPV is important for women's awareness and adherence to the screening program. This study found that only 26.9% of women had good knowledge about cervical cancer screening, and similarly, only 20.1% of women who had heard about HPV had good knowledge about it. Providing information about these topics could improve women's knowledge and increase their participation in screening procedures.
Review
Public, Environmental & Occupational Health
Mohan Narasimhamurthy, Santhosh Upadhyaya Kafle
Summary: Nepal has a high burden of cervical cancer due to limited screening programs. Despite efforts by the Ministry of Health and Population and international collaborations, the current prevention and treatment methods are inadequate to meet WHO's goals. This article provides an overview of Nepal's efforts to address the growing burden of cervical cancer and discusses potential challenges and solutions.
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Medicine, General & Internal
Rebecca B. Perkins, Nicolas Wentzensen, Richard S. Guido, Mark Schiffman
Summary: Each year in the US, about 100,000 people are treated for cervical precancer, 14,000 are diagnosed with cervical cancer, and 4,000 die from it. Almost all cervical cancers worldwide are caused by certain HPV genotypes. HPV vaccination at ages 9 to 12 can prevent over 90% of cervical precancers and cancers. Cervical cancer can be prevented through screening and treatment of cervical precancer in individuals with a cervix aged 21 to 65.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Multidisciplinary Sciences
Yvonne T. Nartey, Kwabena H. Amo-Antwi, Philip M. Hill, Edward Dassah, Richard O. Asmah, Kofi Nyarko, Ramatu Agambire, Thomas Konney, Joel Yarney, Nelson Damale, Brian Cox
Summary: This study aimed to compare the distribution of high-risk human papillomavirus (HR-HPV) genotypes in women with and without cervical cancer in order to develop a population-based prevention strategy for cervical cancer in Ghana. The results showed that the most common HR-HPV genotypes among women with cervical cancer were 16, 18, 45, 35, and 52, while 66, 52, 35, 43, and 31 were frequently detected in women without cancer. HPV DNA testing and multivalent vaccines targeting HPV 16, 18, 45, and 35 genotypes are crucial for cervical cancer control in Ghana.
